<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42728">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550093</url>
  </required_header>
  <id_info>
    <org_study_id>STU86297</org_study_id>
    <nct_id>NCT02550093</nct_id>
  </id_info>
  <brief_title>The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold</brief_title>
  <official_title>The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxytocin is neurohypophysial peptide that acts mainly as a neuromodulator in the brain.The
      vast majority of basic science studies suggested a large effect of oxytocin in minimizing
      acute pain.Few studies have demonstrated an association between plasma levels of oxytocin
      and pain in humans. Since addictive properties of oxytocin have not been described, the drug
      may have important application in the management of acute and chronic pain. No studies have
      examined the effect of intranasal oxytocin on pain sensitivity and threshold.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline of hot and cold thermal threshold for pain</measure>
    <time_frame>up to 2 hrs</time_frame>
    <description>Changes from baseline of hot and cold sensory thermal threshold for pain utilizing the Medoc Pathway Pain &amp;Sensory Evaluation System (Medoc Ltd, Israel) at baseline before drug administration, at 45 minutes and at 90 minutes. Celsius Units.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of mechanical pain threshold</measure>
    <time_frame>up to 2 hrs</time_frame>
    <description>Using a Visual Analog Scale (VAS) subjects will be asked to rate the painfulness of the stimulus utilizing a digital electrovonfrey anesthesiometer (IITC model Alemo 2290-4; Woodland Hills, CA, USA) at its worst at 30 second intervals. Units in grams</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of suprathreshold magnitude</measure>
    <time_frame>up to 2 hrs</time_frame>
    <description>Changes from baseline of suprathreshold magnitude assessment utilizing the Medoc Pathway System with contact heat evoked potential stimulator (CHEPS) at 30 second intervals. Measured at VAS (0-10).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline of thermal wind-up pain</measure>
    <time_frame>up to 2 hrs</time_frame>
    <description>Using a Visual Analog Scale (VAS) subjects will be asked to rate the painfulness of the stimulus for thermal wind-up pain utilizing the medoc pathway system with CHEPS thermode at 30 second intervals. Measured as counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects</measure>
    <time_frame>up to 2 hrs</time_frame>
    <description>Incidence of side effects from oxytocin administration (n, %)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>0.9% Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females volunteers, English speaking

        Exclusion Criteria:

          -  Pregnancy, lactation, allergy to preservatives, mental disease, any chronic pain and
             any current use of analgesics, anxiety or depression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Walega, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 21, 2016</lastchanged_date>
  <firstreceived_date>April 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>David Walega</investigator_full_name>
    <investigator_title>Associate Professor, Chief, Division of Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
